Aspirin and Colon Cancer Recurrence Risk
- A new study published in The New England Journal of Medicine suggests that a daily low-dose aspirin regimen (160mg) can substantially reduce the risk of colorectal cancer recurrence...
- Those with the PIK3 pathway mutation who took daily aspirin experienced roughly half the rate of cancer recurrence compared to the placebo group.
- The PIK3 pathway is a signaling pathway crucial for cell growth, proliferation, and survival.
“`html
Daily Aspirin May Reduce Colorectal Cancer Recurrence in Specific Genetic Profiles
What Happened?
A new study published in The New England Journal of Medicine suggests that a daily low-dose aspirin regimen (160mg) can substantially reduce the risk of colorectal cancer recurrence in survivors with specific genetic mutations within the PIK3 pathway. The research, conducted in Sweden, followed nearly 3,000 colorectal cancer survivors post-surgery. Participants were randomly assigned to either aspirin or a placebo for three years.
Those with the PIK3 pathway mutation who took daily aspirin experienced roughly half the rate of cancer recurrence compared to the placebo group. This finding positions aspirin as a potential “precision medicine” treatment, tailoring therapy based on an individual’s genetic makeup.
Understanding the PIK3 Pathway and its Role in Colorectal Cancer
The PIK3 pathway is a signaling pathway crucial for cell growth, proliferation, and survival. Mutations in genes within this pathway are common in various cancers, including colorectal cancer. These mutations can lead to uncontrolled cell growth and contribute to tumor development and progression.
Approximately one-third of the colorectal cancer survivors in the study had tumors with a mutation in the PIK3 pathway. This suggests that a substantial portion of patients could potentially benefit from aspirin therapy if they carry this specific genetic alteration.
Study Details and Methodology
The study involved 2,963 colorectal cancer survivors who had undergone surgery to remove their tumors.Participants were categorized based on the presence or absence of a PIK3 pathway mutation. They were then randomly assigned to receive either 160mg of aspirin daily or a placebo for three years.
The primary outcome measured was cancer recurrence. Researchers found a statistically significant reduction in recurrence rates among those with the PIK3 mutation who took aspirin compared to those who received the placebo.
| Group | PIK3 Mutation Present (%) | Recurrence Rate (Aspirin) | Recurrence Rate (Placebo) |
|---|---|---|---|
| Aspirin | ~33% | ~10% | ~20% |
| Placebo | ~33% | ~15% | ~30% |
Aspirin is being tested here in a completely new context: as a precision medicine treatment
, stated Dr. Anna Martling, the lead study author.
Who is Affected?
This research primarily impacts individuals diagnosed with early-stage (Stage 1, 2, or 3) colorectal cancer who have a mutation in the PIK3 pathway. It’s crucial to note that this is not a universal proposal for all colorectal cancer survivors.
Determining whether a patient has this mutation requires genetic testing of their tumor tissue. This testing is becoming increasingly common in cancer diagnosis and treatment planning.